Do analysts rate ELYM or SEPN?

Septerna has a consensus target price of $45.89, indicating a potential upside of 38.64%. Given Septerna's stronger consensus rating and higher probable upside, analysts clearly believe Septerna is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Septerna 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.82

Do analysts prefer XNCR or ELYM?

Xencor currently has a consensus price target of $24.25, indicating a potential upside of 24.74%. Given Xencor's stronger consensus rating and higher possible upside, equities research analysts clearly believe Xencor is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xencor 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer XERS or ELYM?

Xeris Biopharma presently has a consensus target price of $10.80, suggesting a potential upside of 29.81%. Given Xeris Biopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Xeris Biopharma is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xeris Biopharma 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend ELYM or MLTX?

MoonLake Immunotherapeutics has a consensus price target of $24.21, suggesting a potential upside of 27.31%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MoonLake Immunotherapeutics 3 Sell rating(s) 4 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.41

Which has higher earnings & valuation, ELYM or MLTX?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.87 N/A

Is ELYM or MLTX more profitable?

Eliem Therapeutics' return on equity of -47.03% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% MoonLake Immunotherapeutics N/A -85.15% -60.52%

Do analysts recommend ELYM or PAHC?

Phibro Animal Health has a consensus price target of $42.50, suggesting a potential upside of 24.89%. Given Phibro Animal Health's stronger consensus rating and higher possible upside, analysts clearly believe Phibro Animal Health is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Phibro Animal Health 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Eliem Therapeutics (ELYM) Competitors

$12.84 +0.08 (+0.63%)

As of 07/24/2026

Compare

ELYM vs. SEPN, XNCR, XERS, MLTX, and PAHC

Should you buy Eliem Therapeutics stock or one of its competitors? MarketBeat compares Eliem Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eliem Therapeutics include Septerna (SEPN), Xencor (XNCR), Xeris Biopharma (XERS), MoonLake Immunotherapeutics (MLTX), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry.

How does Eliem Therapeutics compare to Septerna?

Eliem Therapeutics (NASDAQ:ELYM) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

Eliem Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Septerna	-49.88%	-12.72%	-8.87%

Eliem Therapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the broader market. Comparatively, Septerna has a beta of 2.29, indicating that its share price is 129% more volatile than the broader market.

In the previous week, Septerna had 2 more articles in the media than Eliem Therapeutics. MarketBeat recorded 2 mentions for Septerna and 0 mentions for Eliem Therapeutics. Septerna's average media sentiment score of 0.88 beat Eliem Therapeutics' score of 0.00 indicating that Septerna is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Septerna	Positive

69.8% of Eliem Therapeutics shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by insiders. Comparatively, 5.8% of Septerna shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Eliem Therapeutics has higher earnings, but lower revenue than Septerna. Septerna is trading at a lower price-to-earnings ratio than Eliem Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Septerna	$72.26M	20.65	-$48.88M	-$0.81	N/A

Septerna has a consensus target price of $45.89, indicating a potential upside of 38.64%. Given Septerna's stronger consensus rating and higher probable upside, analysts clearly believe Septerna is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

Septerna beats Eliem Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Eliem Therapeutics compare to Xencor?

Xencor (NASDAQ:XNCR) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

69.8% of Eliem Therapeutics shares are owned by institutional investors. 5.1% of Xencor shares are owned by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Eliem Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
Eliem Therapeutics	N/A	-47.03%	-45.97%

Xencor has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the broader market.

In the previous week, Xencor had 5 more articles in the media than Eliem Therapeutics. MarketBeat recorded 5 mentions for Xencor and 0 mentions for Eliem Therapeutics. Xencor's average media sentiment score of 0.88 beat Eliem Therapeutics' score of 0.00 indicating that Xencor is being referred to more favorably in the media.

Company	Overall Sentiment
Xencor	Positive
Eliem Therapeutics	Neutral

Xencor currently has a consensus price target of $24.25, indicating a potential upside of 24.74%. Given Xencor's stronger consensus rating and higher possible upside, equities research analysts clearly believe Xencor is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Eliem Therapeutics has lower revenue, but higher earnings than Xencor. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	11.48	-$91.92M	-$2.29	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Summary

Xencor beats Eliem Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Eliem Therapeutics compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Xeris Biopharma has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, meaning that its stock price is 139% less volatile than the broader market.

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Xeris Biopharma has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	4.92	$550K	$0.06	138.67
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Xeris Biopharma presently has a consensus target price of $10.80, suggesting a potential upside of 29.81%. Given Xeris Biopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Xeris Biopharma is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Xeris Biopharma has a net margin of 3.81% compared to Eliem Therapeutics' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Eliem Therapeutics	N/A	-47.03%	-45.97%

In the previous week, Xeris Biopharma had 3 more articles in the media than Eliem Therapeutics. MarketBeat recorded 3 mentions for Xeris Biopharma and 0 mentions for Eliem Therapeutics. Xeris Biopharma's average media sentiment score of 1.64 beat Eliem Therapeutics' score of 0.00 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Xeris Biopharma	Very Positive
Eliem Therapeutics	Neutral

Summary

Xeris Biopharma beats Eliem Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Eliem Therapeutics compare to MoonLake Immunotherapeutics?

Eliem Therapeutics (NASDAQ:ELYM) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Eliem Therapeutics' return on equity of -47.03% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

In the previous week, MoonLake Immunotherapeutics had 15 more articles in the media than Eliem Therapeutics. MarketBeat recorded 15 mentions for MoonLake Immunotherapeutics and 0 mentions for Eliem Therapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.74 beat Eliem Therapeutics' score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
MoonLake Immunotherapeutics	Positive

Eliem Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

MoonLake Immunotherapeutics has a consensus price target of $24.21, suggesting a potential upside of 27.31%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

Eliem Therapeutics has a beta of -0.39, suggesting that its stock price is 139% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Summary

MoonLake Immunotherapeutics beats Eliem Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Eliem Therapeutics compare to Phibro Animal Health?

Eliem Therapeutics (NASDAQ:ELYM) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Phibro Animal Health has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Phibro Animal Health	$1.30B	1.06	$48.26M	$2.33	14.61

Eliem Therapeutics has a beta of -0.39, suggesting that its stock price is 139% less volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Phibro Animal Health had 4 more articles in the media than Eliem Therapeutics. MarketBeat recorded 4 mentions for Phibro Animal Health and 0 mentions for Eliem Therapeutics. Phibro Animal Health's average media sentiment score of 1.59 beat Eliem Therapeutics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Phibro Animal Health	Very Positive

Phibro Animal Health has a consensus price target of $42.50, suggesting a potential upside of 24.89%. Given Phibro Animal Health's stronger consensus rating and higher possible upside, analysts clearly believe Phibro Animal Health is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Phibro Animal Health has a net margin of 6.35% compared to Eliem Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Phibro Animal Health	6.35%	37.14%	8.57%

Summary

Phibro Animal Health beats Eliem Therapeutics on 15 of the 15 factors compared between the two stocks.

Get Eliem Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELYM vs. The Competition

Export

Metric	Eliem Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$382.02M	$975.11M	$6.87B	$12.26B
Dividend Yield	N/A	4.84%	2.67%	9.79%
P/E Ratio	-24.23	1.53	27.14	23.64
Price / Sales	N/A	105.75	517.06	88.99
Price / Cash	N/A	20.06	50.54	59.64
Price / Book	3.29	8.47	10.28	6.07
Net Income	-$35.12M	-$2.70M	$3.60B	$331.99M
7 Day Performance	1.10%	-2.29%	-1.27%	-0.63%
1 Month Performance	0.71%	-3.97%	-0.37%	-2.00%
1 Year Performance	767.57%	27.39%	18.30%	13.62%

Eliem Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELYM Eliem Therapeutics	N/A	$12.84 +0.6%	N/A	+762.2%	$382.02M	N/A	N/A	9
SEPN Septerna	2.2323 of 5 stars	$34.20 +1.5%	$45.89 +34.2%	+144.1%	$1.52B	$45.95M	N/A	N/A
XNCR Xencor	2.6358 of 5 stars	$19.51 -4.6%	$24.25 +24.3%	+110.4%	$1.52B	$125.58M	N/A	280
XERS Xeris Biopharma	3.7087 of 5 stars	$8.38 -4.6%	$10.80 +28.9%	+60.9%	$1.52B	$291.85M	139.67	290	News Coverage Analyst Upgrade
MLTX MoonLake Immunotherapeutics	3.1973 of 5 stars	$18.94 -5.6%	$24.21 +27.8%	-65.4%	$1.48B	N/A	N/A	2	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELYM) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eliem Therapeutics (ELYM) Competitors

ELYM vs. SEPN, XNCR, XERS, MLTX, and PAHC

How does Eliem Therapeutics compare to Septerna?

Summary

How does Eliem Therapeutics compare to Xencor?

Summary

How does Eliem Therapeutics compare to Xeris Biopharma?

Summary

How does Eliem Therapeutics compare to MoonLake Immunotherapeutics?

Summary

How does Eliem Therapeutics compare to Phibro Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELYM vs. The Competition

Eliem Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eliem Therapeutics (ELYM) Competitors

ELYM vs. SEPN, XNCR, XERS, MLTX, and PAHC

How does Eliem Therapeutics compare to Septerna?

Is ELYM or SEPN more profitable?

Which has more volatility & risk, ELYM or SEPN?

Does the media refer more to ELYM or SEPN?

Do insiders & institutionals believe in ELYM or SEPN?

Which has better valuation and earnings, ELYM or SEPN?

Do analysts rate ELYM or SEPN?

Summary

How does Eliem Therapeutics compare to Xencor?

Do institutionals and insiders have more ownership in XNCR or ELYM?

Is XNCR or ELYM more profitable?

Which has more risk & volatility, XNCR or ELYM?

Does the media prefer XNCR or ELYM?

Do analysts prefer XNCR or ELYM?

Which has preferable valuation and earnings, XNCR or ELYM?

Summary

How does Eliem Therapeutics compare to Xeris Biopharma?

Which has more volatility & risk, XERS or ELYM?

Do institutionals & insiders have more ownership in XERS or ELYM?

Which has stronger earnings & valuation, XERS or ELYM?

Do analysts prefer XERS or ELYM?

Is XERS or ELYM more profitable?

Does the media favor XERS or ELYM?

Summary

How does Eliem Therapeutics compare to MoonLake Immunotherapeutics?

Is ELYM or MLTX more profitable?

Does the media refer more to ELYM or MLTX?

Which has higher earnings & valuation, ELYM or MLTX?

Do insiders & institutionals have more ownership in ELYM or MLTX?

Do analysts recommend ELYM or MLTX?

Which has more risk & volatility, ELYM or MLTX?

Summary

How does Eliem Therapeutics compare to Phibro Animal Health?

Which has higher earnings & valuation, ELYM or PAHC?

Which has more risk & volatility, ELYM or PAHC?

Do insiders & institutionals have more ownership in ELYM or PAHC?

Does the media refer more to ELYM or PAHC?

Do analysts recommend ELYM or PAHC?

Is ELYM or PAHC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELYM vs. The Competition

Eliem Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools